S-1/A: Mustang Bio Eyes $5 Million Capital Raise Through Stock and Warrant Offering

Mustang Bio is seeking to raise up to $5 million through a public offering of common stock and warrants to fund working capital and pipeline development.

Summary

• Mustang Bio, a clinical-stage biopharmaceutical company, has filed an amendment to its S-1 registration statement for a proposed public offering.
• The offering includes up to 15,625,000 shares of common stock and accompanying warrants, or pre-funded warrants and accompanying warrants, with an assumed combined public offering price of $0.32 per share and warrants.
• The warrants have an exercise price of $0.32 per share and varying expiration dates.
• The company intends to use the net proceeds for working capital, pipeline development activities, and general corporate purposes.
• The offering is expected to terminate on May 13, 2024.
• H.C. Wainwright & Co., LLC is acting as the exclusive placement agent for the offering.
• The company's stock is listed on the Nasdaq Capital Market under the symbol MBIO.
• The company recently announced an 81% reduction in its workforce and is facing potential delisting from Nasdaq due to low stockholders' equity.
• The company estimates its cash and cash equivalents were approximately $1.3 million as of March 31, 2024, and cash used in operating activities for the first quarter of 2024 was $5.3 million.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the company's financial challenges, workforce reduction, and potential delisting from Nasdaq, despite the potential of its pipeline and the capital raise.

Positives

• The offering provides Mustang Bio with an opportunity to raise capital for working capital and pipeline development.
• The warrants, if exercised, could provide additional capital to the company.
• The company has a clinical-stage biopharmaceutical pipeline focused on cell and gene therapies.
• The company has received RMAT designation from the FDA for the treatment of relapsed or refractory CD20 positive WM and FL.

Negatives

• The company has incurred substantial operating losses and has an accumulated deficit of $381.0 million as of December 31, 2023.
• The company recently announced an 81% reduction in its workforce to reduce costs.
• The company is facing potential delisting from Nasdaq due to low stockholders' equity.
• The company estimates its cash and cash equivalents were approximately $1.3 million as of March 31, 2024, and cash used in operating activities for the first quarter of 2024 was $5.3 million.
• The company does not expect to initiate its pivotal Phase 2 single-arm clinical trial of MB-106 for the treatment of WM trial in 2024.

Risks

• Investing in the company's securities involves risks, including potential dilution and the lack of a public market for the warrants.
• The company's management has broad discretion over the use of the net proceeds from the offering.
• The company may not raise the amount of capital it believes is required for its business plans.
• There is substantial doubt regarding the company's ability to continue as a going concern.
• The company is reliant on third parties for manufacturing its product candidates.
• The company is subject to a CFIUS review of the sale of its manufacturing facility.

Future Outlook

The company intends to use the net proceeds from this offering for working capital, general corporate purposes and the payment of outstanding payables incurred in the ordinary course. The company intends to rely on third party service providers to conduct study and manufacturing services to advance its priority potential product candidates.

Industry Context

The company operates in the competitive biopharmaceutical industry, focused on cell and gene therapies for cancer and rare genetic diseases. The success of the company depends on the clinical trial results, regulatory approvals, and commercialization of its product candidates.

Comparison to Industry Standards

• It's difficult to directly compare Mustang Bio's financial situation to industry standards without knowing the specific stage of development and pipeline composition of comparable companies.
• However, many clinical-stage biopharmaceutical companies face similar challenges in securing funding and managing cash flow.
• Companies like Cellectis and CRISPR Therapeutics are also focused on cell and gene therapies, but have different financial profiles and market capitalizations.
• The 81% workforce reduction is a significant measure, potentially impacting the pace of research and development compared to peers with more robust staffing.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• Employees have been impacted by the recent workforce reduction.
• The company's ability to develop and commercialize its product candidates could be affected by its financial situation.

Next Steps

• The company intends to seek stockholder approval for the issuance of shares of common stock issuable upon exercise of the Warrants.
• The company intends to use the net proceeds from this offering for working capital, general corporate purposes and the payment of outstanding payables incurred in the ordinary course.
• The company intends to rely on third party service providers to conduct study and manufacturing services to advance its priority potential product candidates.

Key Dates

Keywords

Mustang Bio, public offering, common stock, warrants, capital raise, pipeline development, cell therapy, gene therapy, MBIO, RMAT designation, HC Wainwright